Arrowhead appoints Victoria Vakiener to board as independent director

ARROWHEAD PHARMACEUTICALS, INC.

Victoria Vakiener appointed effective May 2, 2022, as independent director.
She has extensive biotech/commercial experience; former CCO of Epizyme and 20+ years at J&J.
Granted 17,181 restricted stock units vesting over three years as standard director comp.
Ms. Vakiener also serves on board of Chimerix, a clinical-stage biopharma company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Victoria Vakiener

Director

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Effective: 2022-05-02
Filed: May 5, 2022, 7:59 PM ET

the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Victoria Vakiener as an independent director of the Company effective May 2, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Victoria Vakiener was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Victoria Vakiener as an independent director of the Company effective May 2, 2022.

View on SEC.gov

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-142093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.